-+ 0.00%
-+ 0.00%
-+ 0.00%

Quoin Pharmaceuticals Submits Application For Breakthrough Medicine Designation With Saudi Food And Drug Authority For QRX003 To Treat Netherton Syndrome

Benzinga·01/20/2026 13:35:51
Listen to the news

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for QRX003, its lead investigational, late-stage topical product candidate for the treatment of Netherton Syndrome.